VivoSeq
Immunology

Oral Mucositis

99

Pipeline Programs↗

18

Active Trials↗

52

Companies Involved↗

Oral Mucositis is a moderately active landscape with 99 programs across 52 companies. The most active players are Neurim Pharmaceuticals Ltd., Exela Pharma Sciences, LLC., SciClone Pharmaceuticals. 15 therapies are approved with 31 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

70/100

Pipeline Velocity

32/100

Mech. Concentration

15/100

Completion Rate

83/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Neurim Pharmaceuticals Ltd.

1 program

Phase 1E

Exela Pharma Sciences, LLC.

1 program

Phase 1S

SciClone Pharmaceuticals

1 program

Phase 2I

Innovation Pharmaceuticals, Inc.

1 program

Phase 2V

Valerio Therapeutics

1 program

Phase 2CSL Behring logo

CSL Behring

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical6

Zinc Sulfate

Fakultas Kedokteran Universitas Indonesia

Palifermin

Swedish Orphan Biovitrum

Glutamine

Sanofi

N-Acetylcysteine

Novartis

Oxycodone

Protega

Phase 14

Melatonin

Neurim Pharmaceuticals Ltd.

Phenylephrine

Exela Pharma Sciences, LLC.

Ssk12@lip@gsh

The General Hospital of Western Theater Command

AG013

ActoGeniX N.V.

Phase 243

Chlorhexidine Gluconate

Medline Industries

Etoposide

Avyxa

Filgrastim

Eastern Cooperative Oncology Group

Ketamine

Aultman Health Foundation

Celecoxib

Philadelphia Eye Associates

Phase 331

Curcumin

Merck & Co.

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Cyclophosphamide

Baxter Healthcare Corporation

Doxepin Hydrochloride

Alliance for Clinical Trials in Oncology

Fentanyl

Cephalon

Approved15

Clonidine

Boehringer Ingelheim

Sodium Bicarbonate

Abbott

Acetylcysteine

Arbor Pharmaceuticals, Inc.

Nystatin

Good Molecules, LLC

Thalidomide

Bristol-Myers Squibb

Analysis

Modality Breakdown

95%

Small molecule

121 of 128 classified programs — the dominant modality here.

5%ALL OTHERSProtein / enzyme54%Cell therapy22%

Small molecule leads; the ring shows all 128 classified programs, each share of the total. Modality classified for 98% of 133 pipeline programs.

Analysis

Trial Status

129

clinical trials

Completed69 · 53%
Unknown status28 · 22%
Recruiting10 · 8%
Terminated10 · 8%
Not yet recruiting4 · 3%
Withdrawn4 · 3%
Other4 · 3%

Clinical Trials

Trial Activity

129 trials

Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer Patients
Recruiting·WWest China Hospital·Phase 2·NCT07282483·118 enrolled
Efficacy of High-Level Laser Therapy in Managing Oral Mucositis Among Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation
Recruiting·—·N/A·NCT07436650·14 enrolled
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
Recruiting·SSun Yat-sen University·Phase 3·NCT07311772·244 enrolled
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Recruiting·Alliance for Clinical Trials in Oncology·Phase 3·NCT06992427·228 enrolled
Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients.
Recruiting·WWest China Hospital·Phase 2·NCT07339774·128 enrolled
Efficacy of N-acetylcysteine in Preventing Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients.
Recruiting·MMansoura University·Phase 2·NCT06354712·50 enrolled
Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis
Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT07029178·160 enrolled
Hydroxychloroquine Sulfate Tablets for Radiation-induced Oral Mucositis
Recruiting·—·Phase 1/2·NCT06939582·158 enrolled
Spirulina-Derived Product Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors
Recruiting·WWest China Hospital·Phase 2·NCT07040969·70 enrolled
Study for Dexamethasone Mouthwash in Lowering Episodes of Oral Mucositis Among Patients With Cancer: The SMILE Study
Recruiting·WWoman's·Approved·NCT07287826·45 enrolled
Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT
Active, not recruiting·MMitoImmune Therapeutics·Phase 2·NCT05493800·60 enrolled
A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Active, not recruiting·EEpicentRx, Inc.·Phase 2·NCT05966194·216 enrolled
Photobiomodulation in the Prevention and Management of Oral Mucositis in Children
Not yet recruiting·UUniversidad de Guanajuato·N/A·NCT07372443·49 enrolled
Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT07400328·22 enrolled
Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse
Not yet recruiting·UUniversity of Oklahoma·Phase 2·NCT06660017·62 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)